Evidence map›Paper›PMID 34582645›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

MicroRNA-199: A Potential Therapeutic Tool for Hepatocellular Carcinoma in an Experimental Model.

Shimaa Atta, Nabila El Kramani, Sara Reda Mohamed, Menna Adel Mohamed, Sara Hesham Hassan, Reem Hesham, Aya Mostafa Mohamed, Eman Eid Abdel Halim, Yasmeen Ashraf Mohamed, Eman El-Ahwany

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shimaa AttaImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.ORCID 0000-0003-3915-3453
Nabila El KramaniImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Sara Reda MohamedImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Menna Adel MohamedImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Sara Hesham HassanImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Reem HeshamImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Aya Mostafa MohamedImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Eman Eid Abdel HalimImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Yasmeen Ashraf MohamedImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.
Eman El-AhwanyImmunology Lab, Theodor Bilharz Research Institute, Kornish El Nil street, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is one of the major health problems throughout the world with a very poor prognosis. MicroRNAs are small regulatory non-protein-coding RNA molecules. We aimed at investigating microRNA-199 as a potential therapeutic tool for HCC both in vitro and in an experimental model. A therapeutic strategy based on the effect of microRNAs to target genes responsible for liver cancer was adopted in this work. The ability of these small RNAs to potently influence cellular behavior was also investigated. The role of miR-199a in the development of liver cancer has been identified using a systematic literature search using miRBase. HepG2 cell line was used to test the effect of miRNA199a in vitro. Hepatocellular carcinoma was induced in Male Balb/C mice by diethylnitrosamine (DEN). Mice were treated with miRNA-199a and sacrificed after 16 weeks and blood samples and liver specimens were collected for biochemical and histopathological assessment. Histopathological examination of liver specimens after miRNA 199a treatment showed regression of Hepatocellular carcinoma with restoration of normal architecture. AFP, VEGF and TNFα levels decreased after treatment with miRNA 199a. Caspase 3 and 9; showed decreased expression in animals treated with miRNA 199a than non-treated ones.

Indexed as

AnimalsCarcinoma, HepatocellularHep G2 CellsHumansLiver NeoplasmsMaleMiceMice, Inbred BALB CMicroRNAsModels, TheoreticalMicroRNAsmirn199 microRNA, humanMirn199 microRNA, mousecaspaseKey words: HCCMiRNA199aTNFAVEGF

Identifiers

PMID34582645
PMCPMC8850877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.